PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30340853-5	2018	Results of the present study indicated that the treatment with the PTGFR agonist, fluprostenol, resulted in an increase in abundance of proteins for PTGS-2, vascular endothelial growth factor (VEGF), connective tissue growth factor (CTGF), transforming growth factor beta 1 (TGF-beta1), and interleukin-8 (IL-8).	fluprostenol	82-94	vascular endothelial growth factor A	Bos taurus	157-191	
30340853-5	2018	Results of the present study indicated that the treatment with the PTGFR agonist, fluprostenol, resulted in an increase in abundance of proteins for PTGS-2, vascular endothelial growth factor (VEGF), connective tissue growth factor (CTGF), transforming growth factor beta 1 (TGF-beta1), and interleukin-8 (IL-8).	fluprostenol	82-94	vascular endothelial growth factor A	Bos taurus	193-197	
30340853-8	2018	Additionally, treatment with the PKC inhibitor, chelerythrine, reduced the fluprostenol-induced increase in the relative abundance of VEGF, CTGF, TGF-beta1, and IL-8 mRNA in bEECs.	fluprostenol	75-87	vascular endothelial growth factor A	Bos taurus	134-138